November is Lung Cancer Awareness Month



Lung cancer is the number one form of cancer that kills both men and women in the United States. This year alone, more than 221,130 Americans are expected to be diagnosed with the disease, approximately 156,940 people will die.

In August, 2005, The National Cancer Institute (NCI) announced an integrated effort to eliminate the suffering and death due to lung cancer by 2015. As part of this integrated implementation plan, three critical strategies are being targeted:

  • Reducing the risk for lung cancer by achieving more effective tobacco control
  • Improving the likelihood of a cure through earlier detection and treatment of lung cancer and pre-cancer
  • Introduction of novel targeted therapies through cohesive partnerships with ongoing or planned biology initiatives

Arizona Oncology plays a major role in the battle against lung cancer by providing easy access a full range of advanced cancer care services for patients fighting lung cancer. Our medical and radiation oncologists and their staffs provide chemotherapy, injections, infusion services, radiation therapy and diagnostic imaging services in a setting that allows patients to remain close to their homes and their support network of family and friends. As a result, patients access the best possible treatment with the least amount of disruption to their daily lives. 

Through its affiliation with US Oncology, one of the nation’s largest healthcare services networks dedicated exclusively to cancer treatment and research, Arizona Oncology also brings opportunities to participate in the ongoing clinical research and development of the newest promising cancer therapies to patients throughout Arizona.

“Clinical trial availability is critical for cancer researchers and patients alike,” adds Dr. Michael Roberts, medical oncologist at Arizona Oncology.  “Because of the vast number of trials under way at any one time, there is a great need for patients who meet participation criteria. Community-based oncology centers, such as ours, play a major role in identifying patients who qualify, while also extending the reach of promising investigational therapies to more patients.”